Search

Displaying results 1321 - 1330 of 10000 in total
  1. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].

  2. Drug

    Donepezil

    go.drugbank.com/drugs/DB00843
    ApprovedInvestigational

    Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia. … [L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia.

    International brands: Nomi-NoxMixtures: DOMINGO 5/5/80 MG EFERVESAN TABLET, 30 ADET, DOMINGO 5/5/80 MG EFERVESAN TABLET, 90 ADET
  3. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. … The pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue

    Categories: Interleukin-5 AntagonistProducts: NUCALA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML, NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/ML
  4. Drug

    Norgestimate

    go.drugbank.com/drugs/DB00957
    ApprovedInvestigational

    [A191068] It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. … [A191068] It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.

    Mixtures: TriNessa Lo, TriNessa LoCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  5. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    [L11022] Remestemcel-L was later approved by the FDA on December 18, 2024. … of the recipients [A31818]. aGvHD is often characterized by the presence of inflammatory cascades through signalling of activated T cells.

    Synonyms: Remestemcel-L
  6. Drug

    Tafenoquine

    go.drugbank.com/drugs/DB06608
    ApprovedInvestigational

    Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.

    Categories: MATE 1 Inhibitors, MATE 2 Inhibitors
  7. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.

    Products: COSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 150MG/ML, Fraizeron 150mg/ml solution for injection in pre-filled pen
  8. Indication

    Congenital Adrenal Hyperplasia (CAH)

    go.drugbank.com/conditions/DBCOND0033416
    Drugs: Betamethasone · Bupivacaine · Cortisone acetate · Crinecerfont · Dexamethasone · Hydrocortisone +7 more
    Synonyms: CAH - Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia (CAH)
  9. Indication

    Coronary Artery Disease (CAD)

    go.drugbank.com/conditions/DBCOND0032937
    Drugs: Amlodipine · Atorvastatin · Gemfibrozil
    Synonyms: CAD, Coronary Artery Disease (CAD)
  10. Drug

    Gemcitabine

    go.drugbank.com/drugs/DB00441
    ApprovedInvestigational

    Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. … [L32960] The structure, metabolism, and mechanism of action of gemcitabine are similar to [cytarabine], but gemcitabine has a wider spectrum of antitumour activity.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein substratesSynonyms: 2'-Deoxy-2',2'-difluorocytidine, 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one